Stefania Infusino
Overview
Explore the profile of Stefania Infusino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
164
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gadaleta-Caldarola G, Lanotte L, Infusino S, Gadaleta-Caldarola A, Schipilliti F, Citrigno C, et al.
Cancer Treat Res Commun
. 2023 Nov;
37:100775.
PMID: 37956525
Background: TROP-2 is emerging as a valid and fruitful strategy in triple-negative breast cancer (TNBC) patients, and several agents are currently under evaluation, including Datopotamab deruxtecan (Dato-DXd). Research Design And...
2.
Divella R, Marino G, Infusino S, Lanotte L, Gadaleta-Caldarola G, Gadaleta-Caldarola G
Nutrients
. 2023 Apr;
15(7).
PMID: 37049508
A healthy diet and an active lifestyle are both effective ways to prevent, manage, and treat many diseases, including cancer. A healthy, well-balanced diet not only ensures that the body...
3.
Gadaleta-Caldarola G, Rizzo A, Dadduzio V, Lombardi L, Gadaleta-Caldarola A, Infusino S, et al.
Curr Oncol
. 2022 Oct;
29(10):7925-7931.
PMID: 36290903
Cholangiocarcinoma (CCA) is the second most frequent primary liver cancer, following hepatocellular carcinoma (HCC). Progress in the molecular understanding of CCA has led to the development of several agents, including...
4.
Gadaleta-Caldarola G, Nenna R, Lanotte L, Doronzo A, Gadaleta-Caldarola A, Roma I, et al.
Future Oncol
. 2021 Feb;
17(8):955-963.
PMID: 33538176
Metaplastic breast cancer (MPBC) is a rare and aggressive tumor type in great need of satisfactory therapies. Although most cases of MPBC are 'triple negative', they are nonetheless related to...
5.
Gadaleta-Caldarola G, Divella R, Mazzocca A, Infusino S, Ferraro E, Filippelli G, et al.
Future Oncol
. 2015 Aug;
11(16):2263-6.
PMID: 26260805
No abstract available.
6.
Gadaleta-Caldarola G, Infusino S, Divella R, Ferraro E, Mazzocca A, De Rose F, et al.
Future Oncol
. 2015 Jul;
11(13):1863-80.
PMID: 26161924
Sorafenib is an oral multikinase inhibitor with anticancer activity against a wide spectrum of cancers. It is currently approved for the treatment of patients with hepatocellular carcinoma, advanced renal cell...
7.
Gadaleta-Caldarola G, Infusino S, Galise I, Ranieri G, Vinciarelli G, Fazio V, et al.
Oncol Lett
. 2014 Sep;
8(4):1783-1787.
PMID: 25202410
The standard treatment for advanced hepatocellular carcinoma (HCC) is sorafenib, a multikinase inhibitor of tumor cell proliferation and angiogenesis. Hyperthermia inhibits angiogenesis and promotes apoptosis. Potential synergic antiangiogenic and proapoptotic...
8.
Leporini C, Saullo F, Filippelli G, Sorrentino A, Lucia M, Perri G, et al.
J Pharmacol Pharmacother
. 2013 Dec;
4(Suppl 1):S78-85.
PMID: 24347989
Introduction: The epidermal growth factor receptor inhibitors (EGFRIs), cetuximab and panitumumab, represent an effective treatment option for patients affected by metastatic colorectal cancer (mCRC); furthermore, they are relatively devoid of...
9.
Mastroianni C, Viscomi C, Ceniti S, De Simone R, Filice A, Gadaleta Caldarola G, et al.
Patient
. 2012 Jan;
1(3):181-7.
PMID: 22272925
Background: In recent years, patient-reported outcomes such as health-related quality of life have become important areas of clinician focus in general cancer management. Patients' preferences for, and/or satisfaction with, oral...
10.
De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, et al.
Cancer
. 2004 Jan;
100(2):270-8.
PMID: 14716760
Background: To the authors' knowledge, little is known to date regarding the prognostic relevance of measuring serum levels of vascular endothelial growth factor (VEGF), a potent stimulator of angiogenesis, in...